I guess what I'd like to see at some point, then, if it could be provided to the committee, is something showing where there has been a gradual decline. I'm looking at numbers that suggest otherwise, based on what we've been provided. Maybe the 2008 report will shed some light on that for us.
Previously there was a concern raised about patented pharmaceutical products for human use and new active substances that are entering the marketplace. Because of the increased volume, the PMPRB required additional funding. The note I have is that the 2007 annual report actually reveals that the number of products and active substances fluctuates on a yearly basis, but the trend remains consistent. If the number of new substances is actually consistent with previous years, what would be the motivation for an increase?